EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

Karlijn Hummelink iD, Vincent van der Noort iD, Mirte Muller, Robert D Schouten iD, Michel M van den Heuvel iD, Daniela S Thommen iD, Egbert F Smit iD, Gerrit A Meijer, Kim Monkhorst

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0293707 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Karlijn Hummelink und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadequately examined. In this study, we assessed the combined predictive performance of multiple biomarkers in NSCLC patients treated with nivolumab.

Methods

Pretreatment samples from 135 patients receiving nivolumab were used to evaluate the predictive performance of CD8 tumor-infiltrating lymphocytes (TILs), intratumoral (IT) localization of CD8 TILs, PD-1 high expressing TILs (PD1 T TILs), CD3 TILs, CD20 B-cells, tertiary lymphoid structures (TLS), PD-L1 tumor proportion score (TPS) and the Tumor Inflammation score (TIS). Patients were randomly assigned to a training (n = 55) and validation cohort (n = 80). The primary outcome measure was Disease Control at 6 months (DC 6m) and the secondary outcome measure was DC at 12 months (DC 12m).

Results

In the validation cohort, the two best performing composite biomarkers (i.e. CD8+IT-CD8 and CD3+IT-CD8) demonstrated similar or lower sensitivity (64% and 83%) and NPV (76% and 85%) compared to individual biomarkers PD-1 T TILs and TIS (sensitivity: 72% and 83%, NPV: 86% and 84%) for DC 6m, respectively. Additionally, at 12 months, both selected composite biomarkers (CD8+IT-CD8 and CD8+TIS) demonstrated inferior predictive performance compared to PD-1 T TILs and TIS alone. PD-1 T TILs and TIS showed high sensitivity (86% and 100%) and NPV (95% and 100%) for DC 12m. PD-1 T TILs could more accurately discriminate patients with no long-term benefit, as specificity was substantially higher compared to TIS (74% versus 39%).

Conclusion

Composite biomarkers did not show improved predictive performance compared to PD-1 T TILs and TIS alone for both the 6- and 12-month endpoints. PD-1 T TILs and TIS identified patients with DC 12m with high sensitivity. Patients with no long-term benefit to PD-1 blockade were most accurately identified by PD-1 T TILs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorLymphocytes, Tumor-InfiltratingProgrammed Cell Death 1 ReceptorNivolumabHumansMaleFemaleMiddle AgedAgedImmune Checkpoint InhibitorsTreatment OutcomeAdultCD8-Positive T-Lymphocytes

Substanzen

Biomarkers, TumorProgrammed Cell Death 1 ReceptorNivolumabImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Thoracic Oncology, Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Karlijn Hummelink, Vincent van der Noort, Robert D Schouten, Michel M van den Heuvel, Daniela S Thommen, Egbert F Smit

Zitieren

APA

Hummelink, K., van der Noort, V., Muller, M., Schouten, R. D., van den Heuvel, M. M., Thommen, D. S., Smit, E. F., Meijer, G. A., & Monkhorst, K. (2024). Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0293707

Vancouver

Hummelink K, van der Noort V, Muller M, Schouten RD, van den Heuvel MM, Thommen DS, et al. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0293707

BibTeX
@article{Hummelink2024,
  author = {Hummelink, Karlijn and van der Noort, Vincent and Muller, Mirte and Schouten, Robert D and van den Heuvel, Michel M and Thommen, Daniela S and Smit, Egbert F and Meijer, Gerrit A and Monkhorst, Kim},
  title = {Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0293707}
}
Kostenlos starten →